HTG Molecular Diagnostics (NASDAQ: HTGM) and Oxford Immunotec Global PLC (NASDAQ:OXFD) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations and institutional ownership.
This table compares HTG Molecular Diagnostics and Oxford Immunotec Global PLC’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|HTG Molecular Diagnostics||-432.74%||-1,538.49%||-131.17%|
|Oxford Immunotec Global PLC||-34.58%||-35.76%||-21.67%|
This is a summary of current recommendations and price targets for HTG Molecular Diagnostics and Oxford Immunotec Global PLC, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|HTG Molecular Diagnostics||0||1||2||0||2.67|
|Oxford Immunotec Global PLC||0||0||3||0||3.00|
HTG Molecular Diagnostics currently has a consensus price target of $6.17, indicating a potential upside of 177.78%. Oxford Immunotec Global PLC has a consensus price target of $22.33, indicating a potential upside of 30.00%. Given HTG Molecular Diagnostics’ higher possible upside, research analysts plainly believe HTG Molecular Diagnostics is more favorable than Oxford Immunotec Global PLC.
Insider & Institutional Ownership
28.1% of HTG Molecular Diagnostics shares are held by institutional investors. Comparatively, 87.0% of Oxford Immunotec Global PLC shares are held by institutional investors. 7.6% of HTG Molecular Diagnostics shares are held by company insiders. Comparatively, 7.6% of Oxford Immunotec Global PLC shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares HTG Molecular Diagnostics and Oxford Immunotec Global PLC’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|HTG Molecular Diagnostics||$5.50 million||4.62||-$20.90 million||($3.01)||-0.74|
|Oxford Immunotec Global PLC||$97.44 million||4.07||-$23.66 million||($1.50)||-11.45|
HTG Molecular Diagnostics has higher revenue, but lower earnings than Oxford Immunotec Global PLC. Oxford Immunotec Global PLC is trading at a lower price-to-earnings ratio than HTG Molecular Diagnostics, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
HTG Molecular Diagnostics has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500. Comparatively, Oxford Immunotec Global PLC has a beta of -0.11, indicating that its stock price is 111% less volatile than the S&P 500.
Oxford Immunotec Global PLC beats HTG Molecular Diagnostics on 8 of the 13 factors compared between the two stocks.
About HTG Molecular Diagnostics
HTG Molecular Diagnostics, Inc. is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development. The Company’s HTG Edge and HTG EdgeSeq platforms automate the molecular profiling of genes and gene activity using its nuclease protection chemistry on a range of biological samples. The Company’s HTG EdgeSeq chemistry, together with its HTG Edge or HTG EdgeSeq instrumentation and software, automates and adapts its nuclease protection chemistry to enable analysis using next generation sequencing (NGS) instrumentation. The HTG EdgeSeq system utilizes substantially the same sample preparation reagents as its original chemistry, but allows for read out on an NGS instrument.
About Oxford Immunotec Global PLC
Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology. Its T-SPOT.TB test is used to test for tuberculosis (TB), infection and leverages its T-SPOT technology platform, which allows it to measure the response of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions. It offers a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics. It has a series of assays for use in blood screening, building upon its expertise in tick-borne disease. Its T-SPOT. CMV and T-SPOT. PRT tests are part of its product line focused on the transplantation market.
Receive News & Ratings for HTG Molecular Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.